Cancer Network Staff

Sonikpreet Aulakh, MBBS, MD, discussed the shift toward multiomic personalization and tumor microenvironment reprogramming in neuro-oncology.

Explore key insights on operationalizing bispecific antibodies in community oncology, outpatient step-up dosing, and shared staffing infrastructure.

The FDA extends camizestrant review. Plus, promising Bria-IMT survival data and a ctDNA blood test that spots breast cancer recurrence 4 years early.

Findings from a cohort study demonstrated that coexposure to a COVID-19 mRNA vaccine within 90 days of anti–PD-(L)1 treatment improved OS in patients with cancer.

Nathan Goodyear, MD, discussed how structured exercise programs can reprogram the tumor immune microenvironment and enhance therapeutic efficacy.

The FDA has approved the updated Guardant360 Liquid CDx, a blood-based cancer test combining genomic and epigenomic analysis, across multiple tumors.

Sac-TMT demonstrated a significant improvement in PFS vs chemotherapy as first-line treatment for unresectable locally recurrent or metastatic TNBC.

The approval, based on the phase 3 TROPION-Breast02 trial, marks a significant shift in the first-line treatment of patients with mTNBC.

See which trials in lung, gastrointestinal, and genitourinary cancers to be on the lookout for at 2026 ASCO.

A telephone-based weight loss intervention from the phase 3 BWEL trial improved physical function, fatigue, and social role outcomes vs health education alone in patients with stage II to III breast cancer and BMI of at least 27.

The ArteraAI Prostate Test is now available to predict mortality risk and guide treatment for metastatic hormone-sensitive prostate cancer.

The FDA has granted rare pediatric disease designation and orphan drug designation to FL118 for the treatment of osteosarcoma.

The agency set a Prescription Drug User Fee Act target action date for January 6, 2027, for patients with NMIBC with papillary tumors without CIS.

Statistical significance was not met with either dose level of fianlimab plus cemiplimab compared with the control arm for patients with advanced melanoma.

Investigators evaluated how subcutaneous isatuximab affected workflow and safety for patients with multiple myeloma.

Based on data from the DESTINY-Breast11 and DESTINY-Breast05 trials, the FDA has approved T-DXd as neoadjuvant and adjuvant treatment for patients with HER2-positive early breast cancer.

Researchers evaluated how a yoga intervention impacted cancer-related fatigue levels among patients undergoing active treatment for solid tumors.

Nurses at Johns Hopkins Nursing utilized a checklist for the chemotherapy gel administration via nephrostomy tube in patients with urothelial cancer.

Cedars-Sinai investigators transitioned hematology-oncology units to progressive care models to improve safety for patients receiving immunotherapy.

A total of 100 RNs successfully completed the full chemotherapy training program during the 2024 and 2025 evaluation periods.

Results from the phase 3 VOLGA trial demonstrate that perioperative durvalumab plus neoadjuvant enfortumab vedotin significantly improved EFS and OS in MIBC.

Dana Chase, MD, discussed recent shifts in second-line endometrial cancer care, the role of molecular testing, and the potential of antibody-drug conjugates.

Hua-Jay Cherng, MD, explored how ctDNA and MRD are shifting from theoretical markers to actionable clinical tools in DLBCL.

Steven M. Horwitz, MD, discussed the PRIMO dosing strategy to manage adverse effects in lymphoma.

The FDA has granted RMAT designation to RZ-001, a first-in-class RNA trans-splicing ribozyme gene therapy, for the management of hepatocellular carcinoma.

Data from the phase 1/2 RMC-6236-001 trial show that the RAS(ON) multiselective inhibitor daraxonrasib yielded responses in pretreated RAS-mutated PDAC.

Ralph V. Boccia, MD, FACP, discussed the operational hurdles of administering bispecific antibodies in community settings.

Jennifer Effie Amengual, MD, discussed using epigenetic drugs to enhance immune surveillance and other novel lymphoma therapeutic strategies.

Mohamed Adam, MD, discusses switching from open to robotic Whipple procedures and the impending integration of AI-driven navigation in surgical oncology.

The FDA’s decision is based on data from the phase 1/2 eNRGy trial, which demonstrated that zenocutuzumab yielded responses in NRG1+ cholangiocarcinoma.